EUCTR2012-001042-18-ES进行中（未招募）不适用
Booster Effect and Safety of a DTaP-IPV-Hib Combined Vaccine, with or without Hep B, in Healthy Subjects 11 to 18 Months of Age Who Received a Hexavalent or Hexavalent/Pentavalent Combined Vaccine during the Primary Series.
Sanofi Pasteur SA0 个研究点目标入组 795 人开始时间: 2014年12月22日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 795
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •An individual must fulfill all of the following criteria in order to be eligible for trial enrollment:
- •1) Infants/toddlers previously included in Study A3L39 who completed
- •the 3- dose primary series vaccination according to protocol
- •2) Groups 1 and 2 (Germany and the Czech Republic) aged 11 to 15 months on the day of the first study visit; Group 3 (Spain) aged 18 months on the day of the first study visit
- •3) Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative (and by an independent witness if required by local regulations)
- •4) Subject and parent/legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures
- •5) Covered by health insurance, if applicable
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 795
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •An individual fulfilling any of the following criteria is to be excluded from
- •trial enrollment:
- •1) Participation at the time of study enrollment (or 4 weeks preceding the booster vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
- •2) Receipt of any out-of-study vaccines within the 2-week period prior to Visit 01 and within the 4-week period following the receipt of study vaccines or until all Visit 02 study procedures have been completed
- •3) Receipt of immune globulins, blood or blood-derived products in the last 3 months
- •4) Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 3 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- •5) History of diphtheria, tetanus, pertussis, poliomyelitis, Hep B or Haemophilus influenzae type b and pneumococcal infections, confirmed either clinically, serologically, or microbiologically
- •6) Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances
- •7) Known thrombocytopenia, as reported by the parent/legally acceptable representative
- •8) Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination
- •9) Subjects in an emergency setting, or hospitalized involuntarily
- •10) Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
- •11) Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ? 38.0°C). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided.
- •12) Identified as a natural or adopted child of the investigator or employee with direct involvement in the proposed study
- •13) If any of the following events are known to have occurred in temporal relation to the receipt of a pertussis-containing vaccine, the decision to give further doses of pertussis-containing vaccines should be carefully considered:
- •? Encephalopathy
- •? Temperature of ? 40°C within 48 hours not due to another identifiable cause
- •? Collapse of shock-like state (hypotonic-hyporesponsive episode [HHE]) within 48 hours of vaccination
- •? Persistent, inconsolable crying lasting ? 3 hours, occurring within 48 hours if vaccination
- •? Convulsions with or without fever, occurring within 3 days of vaccination
研究者
相似试验
已完成
3 期
Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.Haemophilus Influenzae Type bHepatitis BTetanusPertussisDiphtheriaNCT00313911Sanofi Pasteur, a Sanofi Company2,133
进行中（未招募）
不适用
Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in ChinaHealthy volunteers: active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive infections caused by Haemophilus influenzae type b (such as meningitis, septicaemia, cellulitis, arthritis, epiglottitis, pneumopathy, osteomyelitis)MedDRA version: 18.1Level: LLTClassification code 10036897Term: Prophylactic vaccinationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.1Level: HLGTClassification code 10043413Term: Therapeutic procedures and supportive care NECSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.1Level: PTClassification code 10021430Term: ImmunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.1Level: HLTClassification code 10021431Term: ImmunisationsSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2015-005404-29-Outside-EU/EEASANOFI PASTEUR SA900
招募中
不适用
Influence of BCG vaccine as a booster for TDaP-IPV vaccinatio1002766510002252PertussisWhooping coughNL-OMON40745Radboudumc51
已完成
3 期
DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese InfantsPoliomyelitisBacterial MeningitisDiphtheriaTetanusPertussisNCT02274285Sanofi Pasteur, a Sanofi Company424
进行中（未招募）
1 期
Study to Assess the Immune Response and the Safety Profile of DTaP-IPVHB- PRP~T Combined Vaccine Given Concomitantly or Sequentially with 4CMenB Vaccine in Italian InfantsHaemophilus influenzae type b immunisationMedDRA version: 21.1Level: LLTClassification code 10054181Term: Hepatitis B immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: PTClassification code 10069533Term: Haemophilus influenzae type b immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2019-002585-12-ITSANOFI PASTEUR396